Stock VVY VIVORYON THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam
Other stock markets
 11:35:27 2024-04-26 am EDT 		5-day change 1st Jan Change
0.8 EUR -2.44% Intraday chart for Vivoryon Therapeutics N.V. +76.60% -90.17%
Apr. 24 Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Mar. 15 Vivoryon Therapeutics N.V Announces Resignation of Board of Directors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 21.01 108.7 180 380.4 248.8 20.85 20.85 -
Enterprise Value (EV) 1 21.01 108.7 154 365.7 218.6 193.7 1.303 14.15
P/E ratio -2.72 x -8.77 x -10.9 x -30.2 x -8.06 x -7.27 x -1.12 x 0.97 x
Yield - - - - - - - -
Capitalization / Revenue - - - 35.3 x - -58,614 x - -
EV / Revenue - - - 34 x - -53,497 x - -
EV / EBITDA -2.74 x - -9.71 x -29 x -7.55 x -6.75 x -0.08 x -0.92 x
EV / FCF - - - -32.4 x -10 x -17.6 x -0.1 x -1.03 x
FCF Yield - - - -3.09% -9.96% -5.69% -1,051% -97.5%
Price to Book - - - - 8.57 x - - -
Nbr of stocks (in thousands) 8,208 19,975 19,975 20,020 24,105 26,067 26,067 -
Reference price 2 2.560 5.440 9.010 19.00 10.32 0.8000 0.8000 0.8000
Announcement Date 3/28/19 3/26/20 4/30/21 4/28/22 4/19/23 4/24/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - - - 10.76 - -0.00362 - -
EBITDA 1 -7.675 - -15.86 -12.63 -28.95 -28.67 -16.4 -15.4
EBIT 1 - - -16.01 -12.8 -29.11 -28.84 -18.47 31.97
Operating Margin - - - -118.9% - 796,602.21% - -
Earnings before Tax (EBT) 1 - - -16.51 -12.22 -28.36 -28.58 -18.7 31.8
Net income 1 -7.737 -7.823 -16.51 -12.66 -28.16 -28.34 -18.7 19.13
Net margin - - - -117.57% - 782,928.18% - -
EPS 2 -0.9400 -0.6200 -0.8300 -0.6300 -1.280 -1.120 -0.7167 0.8267
Free Cash Flow 1 - - - -11.28 -21.78 -11.03 -13.7 -13.8
FCF margin - - - -104.84% - 304,613.26% - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/28/19 3/26/20 4/30/21 4/28/22 4/19/23 4/24/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2023 S1 2023 S2
Net sales 1 - - -0.00362
EBITDA - - -
EBIT 1 -3.077 - -18.14
Operating Margin - - 501,243.09%
Earnings before Tax (EBT) 1 - - -17.82
Net income 1 - -10.72 -17.63
Net margin - - 486,906.08%
EPS 2 - -0.4400 -0.6800
Dividend per Share - - -
Announcement Date 7/30/19 9/7/23 4/24/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 - - 26 14.7 30.1 18.5 19.6 6.7
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - -11.3 -21.8 -11 -13.7 -13.8
ROE (net income / shareholders' equity) - - - -59.2% -131% -107% -68.1% -216%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - 1.200 - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.02 - 0.06 0.02 0.01 0.01 - -
Capex / Sales - - - 0.19% - -386.74% - -
Announcement Date 3/28/19 3/26/20 4/30/21 4/28/22 4/19/23 4/24/24 - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.8 EUR
Average target price
41.57 EUR
Spread / Average Target
+5,095.83%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIVORYON THERAPEUTICS N.V. Stock Vivoryon Therapeutics N.V.
-90.17% 22.26M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VVY Stock
  4. Financials Vivoryon Therapeutics N.V.